Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Feedback Inhibition00:46

Feedback Inhibition

57.4K
Biochemical reactions are occurring constantly in cells, converting starting substances to different products, usually with the help of enzymes that speed the reactions. Without enzymes, it would take far too long for most reactions to occur to be useful to the cell!
57.4K
Enzyme Inhibition01:30

Enzyme Inhibition

92.9K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
92.9K
Structure and Function of Platelets01:18

Structure and Function of Platelets

3.8K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
3.8K
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

9.6K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
9.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

6.0K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.0K
Production Efficiency01:01

Production Efficiency

18.7K
Net production efficiency (NPE) is the efficiency at which organisms assimilate energy into biomass for the next trophic level. Due to low metabolic rates and less energy spent on thermoregulatory processes, the NPE of ectotherms (cold-blooded animals) is 10 times higher than endotherms (warm-blooded animals).
18.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Resolving the dilution paradox to improve the interpretation of extracellular vesicle biomarker studies.

Research and practice in thrombosis and haemostasis·2026
Same author

Optimizing revascularization in the high-risk heart: Impella™-facilitated percutaneous coronary intervention in multivessel coronary artery disease with reduced left ventricular ejection fraction and mitral regurgitation.

European heart journal supplements : journal of the European Society of Cardiology·2026
Same author

The Dilution Paradox in Extracellular Vesicle Flow Cytometry.

Journal of extracellular vesicles·2026
Same author

Optimizing Anticoagulation Therapy when Utilizing Mechanical Circulatory Support Devices.

Interventional cardiology clinics·2026
Same author

Response to Letter to the Editor regarding "Lipoprotein(a) and clinical characteristics of Polish patients hospitalized in a tertiary referral hospital - an observational, cross-sectional study".

Cardiology journal·2026
Same author

Immediate versus staged revascularization in acute coronary syndrome and multivessel disease: a meta-analysis and meta-regression of RCTs.

Internal and emergency medicine·2026

Related Experiment Video

Updated: Feb 15, 2026

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
05:49

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

1.2K

Ticagrelor - toward more efficient platelet inhibition and beyond.

Michał J Kubisa1, Mateusz P Jezewski1, Aleksandra Gasecka2,3

  • 1Department of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology (CEPT).

Therapeutics and Clinical Risk Management
|February 6, 2018
PubMed
Summary

Ticagrelor offers superior antiplatelet therapy for acute coronary syndromes (ACS) compared to clopidogrel, with unique reversible P2Y12 inhibition and beneficial pleiotropic effects. However, it carries a higher bleeding risk and potential adverse effects like dyspnea.

Keywords:
P2Y12acute coronary syndromesantiplatelet drugsmyocardial infarctionpleiotropismticagrelor

More Related Videos

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
09:13

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Published on: April 6, 2017

12.5K
Preparation of Pooled Human Platelet Lysate pHPL as an Efficient Supplement for Animal Serum-Free Human Stem Cell Cultures
08:32

Preparation of Pooled Human Platelet Lysate pHPL as an Efficient Supplement for Animal Serum-Free Human Stem Cell Cultures

Published on: October 30, 2009

26.1K

Related Experiment Videos

Last Updated: Feb 15, 2026

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
05:49

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

1.2K
Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
09:13

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Published on: April 6, 2017

12.5K
Preparation of Pooled Human Platelet Lysate pHPL as an Efficient Supplement for Animal Serum-Free Human Stem Cell Cultures
08:32

Preparation of Pooled Human Platelet Lysate pHPL as an Efficient Supplement for Animal Serum-Free Human Stem Cell Cultures

Published on: October 30, 2009

26.1K

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Thrombosis Research

Background:

  • Novel antiplatelet agents are emerging for atherothrombotic conditions.
  • Ticagrelor shows superiority over clopidogrel plus aspirin in acute coronary syndromes (ACS).
  • Ticagrelor uniquely inhibits the P2Y12 receptor reversibly and possesses adenosine-mediated pleiotropic effects.

Purpose of the Study:

  • To review the evidence for ticagrelor's efficacy and safety in ACS and other conditions.
  • To discuss the mechanisms behind ticagrelor's pleiotropic effects and drug interactions.
  • To explore future non-coronary indications for ticagrelor.

Main Methods:

  • Systematic review of large-scale clinical trials.
  • Analysis of pharmacological mechanisms of P2Y12 inhibition and adenosine effects.
  • Evaluation of evidence from ongoing and completed studies in non-ACS populations.

Main Results:

  • Ticagrelor reduces cardiovascular events in ACS patients but increases major bleeding risk.
  • Pleiotropic effects include cardioprotection and anti-inflammatory actions, but adverse effects like dyspnea and bradycardia are associated with increased adenosine.
  • Evidence suggests comparable efficacy and safety of ticagrelor and clopidogrel in extra-coronary indications, pending further trial results.

Conclusions:

  • Ticagrelor is a superior P2Y12 antagonist for ACS, offering significant benefits despite increased bleeding risk.
  • Understanding ticagrelor's pleiotropic effects and adenosine-related adverse events is crucial for patient management.
  • Further research is needed to establish ticagrelor's role in non-coronary atherothrombotic conditions.